Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Antiviral Agents

Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System

G. L. Drusano, P. A. Bilello, W. T. Symonds, D. S. Stein, J. McDowell, A. Bye, J. A. Bilello
G. L. Drusano
1Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Albany Medical College, Albany, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: GLDRUSANO@AOL.COM
P. A. Bilello
1Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Albany Medical College, Albany, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. T. Symonds
2Glaxo-Wellcome, Inc., Research Triangle Park, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. S. Stein
2Glaxo-Wellcome, Inc., Research Triangle Park, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. McDowell
2Glaxo-Wellcome, Inc., Research Triangle Park, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Bye
3Glaxo-Wellcome, Inc., Greenford, Middlesex, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. A. Bilello
1Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Albany Medical College, Albany, New York
4SRA Life Sciences, Rockville, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.46.2.464-470.2002
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Computer simulation of a 500-mg oral dose. Multidose pharmacokinetic data were modeled using the programs in the ADAPT II software package. The points are the computer-simulated weighted means for the patient population. The AUC24 for the 500-mg dose was determined to be 10.08 mg · h/liter. (A) Simulated profile for 500 mg administered once daily. (B) Simulated profile for 250 mg administered q12h.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Comparison of the efficacy of abacavir on cell infection of CEM cells with HIV strains IIIB and MN versus cocultivation of CEM cells with HIV-infected H9 cells at a 100:1 ratio. The dose of drug was 0.42 μg/ml, which was the calculated value for a constant exposure of cells to the simulated 500-mg dose. HIV p24 was measured in cell supernatants of the cultures at day 7 postinfection.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    (a) Effect of abacavir on the spread of HIV strain IIIB. Three bioreactors were set with 3 × 107 CEM cells and 3 × 105 H9 IIIB cells (1:100 I/u). One hollow-fiber bioreactor was exposed to the calculated constant infusion level of a 500-mg dose (0.42 μg/ml abacavir) (▴). The second was exposed to a simulated 500-mg q24h dose (•) using the computer-driven pump to simulate an oral dose. The third was an untreated unit (▪) that was continuously exposed to medium without drug. Samples were taken at the indicated time points, and p24 was measured as indicated. (b) Effect of abacavir on the spread of HIV strain MN. Three bioreactors were set with 3 × 107 CEM cells and 3 × 105 H9 MN cells (1:100 I/u). One hollow-fiber bioreactor was exposed to the calculated constant infusion level of a 500-mg dose (0.42 μg/ml abacavir) (▴). The second was exposed to a simulated 500-mg q24h dose (•) using the computer-driven pump to simulate an oral dose. The third was an untreated unit (▪) that was continuously exposed to medium without drug. Samples were taken at the indicated time points and p24 was measured as indicated. (c) Effect of the schedule on the ability of the same total exposure of abacavir (AUC24 = 10.0838 mg·h/liter) on the spread of HIV strain MN. Three bioreactors were set with 3 × 107 CEM cells and 3 × 105 H9 MN cells (1:100 I/u). One hollow-fiber bioreactor was exposed to the 250-mg q12 dose (▪). The second was exposed to a simulated 500-mg q24h dose (▴) using the computer-driven pumps to simulate an oral dose. The third was an untreated unit (•) that was continuously exposed to medium without drug. Samples were taken at the indicated time points, and p24 was measured as indicated.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Examination of the effect of no therapy and abacavir (300 mg q12h, 600 mg q24h, and 1,200 mg q48h) on the spread of HIV strain HXB-2. Samples for p24 analysis were from cell supernatant fluid from the ECS of individual hollow-fiber units and frozen at −70°C until the samples were taken at the 15- and 30-day points. At day 15 and day 30 samples from each hollow fiber were thawed, diluted, and tested in a p24 antigen capture enzyme-linked immunosorbent assay. The means of two determinations and the SDs are plotted on a linear scale.

PreviousNext
Back to top
Download PDF
Citation Tools
Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System
G. L. Drusano, P. A. Bilello, W. T. Symonds, D. S. Stein, J. McDowell, A. Bye, J. A. Bilello
Antimicrobial Agents and Chemotherapy Feb 2002, 46 (2) 464-470; DOI: 10.1128/AAC.46.2.464-470.2002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pharmacodynamics of Abacavir in an In Vitro Hollow-Fiber Model System
G. L. Drusano, P. A. Bilello, W. T. Symonds, D. S. Stein, J. McDowell, A. Bye, J. A. Bilello
Antimicrobial Agents and Chemotherapy Feb 2002, 46 (2) 464-470; DOI: 10.1128/AAC.46.2.464-470.2002
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-HIV Agents
Dideoxynucleosides
HIV-1

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596